현재 위치：홈 > 뉴스현황 > Our Events > Medicilon Appoints D...
저자：medicilon 업로드：2022-10-20 조회수：
Recently, Shanghai Medicilon Inc. (Medicilon) appointed Dr. Rui Zhang as Senior Vice President of Pharmaceutical Research.
After the appointment, Dr. Zhang will further promote Medicilon's entry into the CDMO field, help Medicilon to establish a large-scale production which meets the GMP standards through strategic collaboration, self-construction or mergers and acquisitions, further improve the crystal form research service platform, and strengthen the small-scale production. The construction of technology platforms in the field of nucleic acid drugs and peptide drug preparations helps Medicilon to achieve the "CRO+CDMO" two-wheel drive. In addition, Dr. Zhang will further promote the business expansion of Medicilon and help Medicilon to empower the research and development of new drugs.
Dr. Rui Zhang, obtained his Ph.D in University of Victoria and post-doctoral fellow at the School of Pharmacy, University of Manitoba. Dr. Zhang has been deeply involved in the field of drug research and development for 15 years, leading the development of 6 small molecule PCC drugs and successfully pushing several small molecule new drug projects to the clinical stage. He has completed a number of NDA, IND, PLGA excipient applications, has been responsible for a number of new drug CMC work, and developed a number of international and domestic leading process projects. He has completed a number of NDA, IND, PLGA applications, has been responsible for a number of new drug CMC work, and developed a number of international and domestic leading process projects. Dr. Zhang has extensive experience in the whole-process development of new drugs, improved new drugs (including high-end preparations) and generic drugs, and will help Medicilon to empower clients in all aspects of new drug research and development, including product development, quality research, change control, production and declaration. Dr. Zhang was selected as a talent in Sichuan Province's "Tianfu Emei Plan", Shandong's "Taishan Industry Leading Talent" and Yantai's "Double Hundred Plan" talent.
Prior joining Medicilon, Dr. Zhang served as the VP of R&D and the Head of the Chemistry Department at Luye Pharma Group, responsible for new drug discovery and new drug development CMC. Before that, Dr. Zhang served as senior executive of Jinan KangHe Pharmaceutical Technology Co., Ltd., AstaTech (Chengdu) Biopharmaceutical Corp., CanAm Bioressearch Inc., CombiPhos Catalysts Inc., accumulating rich experience in drug research and development and team management.
